The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
Table 1
Demographics and baseline characteristics of participants and their differences by the study site.
Variable
Total cohort, n = 22
Site 1-KAUH, n = 12 (54.5%)
Site 2-PHH, n = 10 (45.5%)
value
Female, n (%)
16 (72.7)
9 (75.0)
7 (70.0)
0.793
Age in years, mean (SD)
44.64 (10.40)
42.50 (11.21)
47.21 (9.42)
0.284
Height in cm
n = 15
n = 12
n = 3
0.344
Mean (SD)
165.9 (9.2)
165.1 (9.9)
169.3 (5.9)
Weight in kg
n = 17
n = 12
n = 5
0.512
Mean (SD)
82.7 (15.5)
81.3 (17.1)
86.0 (11.6)
BMI
n = 15
n = 12
n = 3
0.419
Mean (SD)
29.4 (5.9)
29.9 (6.3)
27.6 (3.8)
RA duration in years, mean (SD)
6.19 (5.61)
6.66 (6.10)
5.56 (5.11)
0.645
Min
0
0
2
Max
19.0
19.0
18.0
RF positive, n (%)
22 (100.0)
12 (100.0)
10 (100.0)
—
Concomitant medications:
Methotrexate use, n (%)
19 (86.4)
10 (83.3)
9 (90.0)
0.650
NSAID use, n (%)
8 (36.4)
1 (8.3)
7 (70.0)
0.002
DAS28-ESR
n = 20
n = 12
n = 8
0.603
Mean (SD)
6.52 (0.23)
6.41 (0.89)
6.68 (1.28)
Min
4.20
4.59
4.20
Max
7.90
7.60
7.90
HAQ-DI
n = 20
n = 12
n = 8
0.191
Mean (SD)
0.99 (0.81)
1.18 (0.75)
0.71 (0.81)
Min
0
0
0
Max
2.55
2.40
2.55
ESR, mm/hour
n = 21
n = 11
n = 10
0.059
Mean (SD)
58.57 (26.27)
48.64 (17.55)
69.50 (30.63)
Min
17.00
27.00
17.00
Max
128.00
80.00
128.00
CRPa, mg/l
n = 19
n = 9
n = 10
0.576
Mean (SD)
39.55 (85.72)
52.00 (124.82)
28.34 (23.55)
Min
0
0
5.20
Max
384.00
384.00
76.60
aThree CRP values for two patients were replaced by “0.0” as the principal investigator filled their original values as “Negative.” KAUH: King Abdullah University Hospital; PHH: Prince Hamzah Hospital; BMI: body mass index; RA: rheumatoid arthritis; RF: rheumatoid factor; DAS28: 28-Joint Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; HAQ-DI: Disability Index of the Health Assessment Questionnaire; CRP: C-reactive protein.
